» Articles » PMID: 19512902

Evaluation of a New Tear Osmometer for Repeatability and Accuracy, Using 0.5-microL (500-Nanoliter) Samples

Overview
Journal Cornea
Specialty Ophthalmology
Date 2009 Jun 11
PMID 19512902
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the repeatability and accuracy of a new tear osmometer that measures the osmolality of 0.5-microL (500-nanoliter) samples.

Methods: Four standardized solutions were tested with 0.5-microL (500-nanoliter) samples for repeatability of measurements and comparability to standardized technique. Two known standard salt solutions (290 mOsm/kg H2O, 304 mOsm/kg H2O), a normal artificial tear matrix sample (306 mOsm/kg H2O), and an abnormal artificial tear matrix sample (336 mOsm/kg H2O) were repeatedly tested (n = 20 each) for osmolality with use of the Advanced Instruments Model 3100 Tear Osmometer (0.5-microL [500-nanoliter] sample size) and the FDA-approved Advanced Instruments Model 3D2 Clinical Osmometer (250-microL sample size).

Results: Four standard solutions were used, with osmolality values of 290, 304, 306, and 336 mOsm/kg H2O. The respective precision data, including the mean and standard deviation, were: 291.8 +/- 4.4, 305.6 +/- 2.4, 305.1 +/- 2.3, and 336.4 +/- 2.2 mOsm/kg H2O. The percent recoveries for the 290 mOsm/kg H2O standard solution, the 304 mOsm/kg H2O reference solution, the normal value-assigned 306 mOsm/kg H2O sample, and the abnormal value-assigned 336 mOsm/kg H2O sample were 100.3, 100.2, 99.8, and 100.3 mOsm/kg H2O, respectively.

Conclusions: The repeatability data are in accordance with data obtained on clinical osmometers with use of larger sample sizes. All 4 samples tested on the tear osmometer have osmolality values that correlate well to the clinical instrument method. The tear osmometer is a suitable instrument for testing the osmolality of microliter-sized samples, such as tears, and therefore may be useful in diagnosing, monitoring, and classifying tear abnormalities such as the severity of dry eye disease.

Citing Articles

The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research.

Roy N, Wei Y, Kuklinski E, Asbell P Invest Ophthalmol Vis Sci. 2017; 58(6):BIO1-BIO19.

PMID: 28475698 PMC: 5455411. DOI: 10.1167/iovs.17-21709.


Topical cyclosporine a for treatment of dry eye due to chronic mustard gas injury.

Jadidi K, Panahi Y, Ebrahimi A, Mafi M, Nejat F, Sahebkar A J Ophthalmic Vis Res. 2015; 9(4):417-22.

PMID: 25709764 PMC: 4329699. DOI: 10.4103/2008-322X.150803.


New testing options for diagnosing and grading dry eye disease.

Foulks G, Pflugfelder S Am J Ophthalmol. 2014; 157(6):1122-9.

PMID: 24631478 PMC: 4062650. DOI: 10.1016/j.ajo.2014.03.002.


The Guanine Nucleotide Exchange Factor Brx: A Link between Osmotic Stress, Inflammation and Organ Physiology and Pathophysiology.

Kino T, Segars J, Chrousos G Expert Rev Endocrinol Metab. 2010; 5(4):603-614.

PMID: 21037977 PMC: 2964845. DOI: 10.1586/eem.10.3.


[Meibomian glands : part III. Dysfunction - argument for a discrete disease entity and as an important cause of dry eye].

Knop E, Knop N, Brewitt H, Pleyer U, Rieck P, Seitz B Ophthalmologe. 2009; 106(11):966-79.

PMID: 19941140 DOI: 10.1007/s00347-009-2043-9.